Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

31.71 +0.01 (+0.03%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

32 33 Next >

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗

Today 5:25 EDT

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Via The Motley Fool

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

Via Investor Brand Network

InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

May 13, 2026

Via Investor Brand Network

Viking Therapeutics (NASDAQ:VKTX) Stock Holds Steady After Q1 2026 Earnings Miss on Higher Phase 3 Spending ↗

April 29, 2026

Via Chartmill

Topics Earnings

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

From BioMedWire

Via GlobeNewswire

Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months ↗

May 04, 2026

The Street is bullish on this biotech's prospects, but is the sentiment justified?

Via The Motley Fool

Eli Lilly Just Announced Fantastic News for Shareholders ↗

May 04, 2026

Lilly's weight loss drugs have been delivering blockbuster revenue.

Via The Motley Fool

Topics Earnings

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗

May 01, 2026

Via MarketBeat

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗

April 30, 2026

This particular player has seen its yield rise in recent years.

Via The Motley Fool

This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗

April 26, 2026

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.

Via The Motley Fool

Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗

April 25, 2026

The weight loss drug market may reach almost $100 billion in a few years.

Via The Motley Fool

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

April 23, 2026

From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met

From Equity Insider

Via GlobeNewswire

Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗

April 17, 2026

One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.

Via The Motley Fool

Topics Artificial Intelligence

Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗

April 17, 2026

The stock could have plenty of room to run from current levels.

Via The Motley Fool

Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗

April 04, 2026

The answer to the question might surprise many investors. It pays to be open-minded about risk.

Via The Motley Fool

Topics Economy Energy

Where Will Viking Therapeutics Stock Be in 10 Years? ↗

April 03, 2026

There is a wide range of possibilities.

Via The Motley Fool

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

April 03, 2026

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...

Via MarketMinute

Topics Intellectual Property

Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring

April 02, 2026

Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require...

Via MarketMinute

Topics Economy

2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More ↗

March 31, 2026

There are some tempting bargains if you know where to look.

Via The Motley Fool

1 Reason This Biotech Stock Could Triple Before Year-End ↗

March 29, 2026

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Via The Motley Fool

Why Viking Therapeutics Stock Could Take Off Later This Year ↗

March 23, 2026

Some key clinical trial data is expected soon.

Via The Motley Fool

Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity

March 23, 2026

As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns

March 23, 2026

On March 23, 2026, the small-cap heavy Russell 2000 Index surged by a definitive 3.0%, soundly outperforming the S&P 500 and the Nasdaq Composite in a session characterized by aggressive "risk-on"...

Via MarketMinute

Topics ETFs Economy Stocks

Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗

March 22, 2026

One of these assets is catalyst-driven; the other isn't.

Via The Motley Fool

Topics Intellectual Property

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗

March 17, 2026

Each of these companies could benefit from this high-growth market over time.

Via The Motley Fool

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗

March 16, 2026

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

3 Companies at the Forefront of the GLP-1 Pill Wars ↗

March 16, 2026

Via MarketBeat

Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 ↗

March 11, 2026

The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting data by the end of September.

Via The Motley Fool

VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race ↗

March 11, 2026

Viking says it needs only about 5%-10% market share to succeed in the obesity market, despite competition from Eli Lilly and Novo Nordisk.

Via Stocktwits

The Great Rotation: Russell 2000 Surges as Investors Flee Overstretched Tech Giants

March 10, 2026

NEW YORK — In a dramatic shift of market leadership, the Russell 2000 index (INDEXRUSSELL:RUT) continued its historic outperformance on Tuesday, March 10, 2026, as investors aggressively rotated...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

32 33 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.